{"nctId":"NCT01580670","briefTitle":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","startDateStruct":{"date":"2012-03"},"conditions":["Pediatric Crohn's Disease"],"count":14,"armGroups":[{"label":"TA-650","type":"EXPERIMENTAL","interventionNames":["Drug: TA-650"]}],"interventions":[{"name":"TA-650","otherNames":["Infliximab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have been diagnosed as Crohn's disease at least 3 months prior to screening.\n* Have active Crohn's disease despite adequate conventional therapy.\n\nExclusion Criteria:\n\n* Patients with severe intestinal strictures (strictures which may affect the number of defecations, etc., or dilation of the colon or strictures in the proximal small bowel observed on barium radiograph, or strictures precluding the insertion of endoscope), a diagnosis of short bowel syndrome, or previous stoma surgery.\n* Patients who have a history of treatment with infliximab, or biological products (anti-TNFÎ± agents and anti-IL-6 agents, etc.).","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Patients Who Achieved PCDAI Response","description":"Crohn's Disease Activity Index(PCDAI) response was defined as a case where PCDAI on the evaluation day was decreased by at least 15 points compared to PCDAI in the screening period and decreased to not more than 30.\n\nPCDAI was the sum (0 to 100) of the scores of 5 large categories. A larger PCDAI score represented higher disease activity. 5 large categories were as follows, i.e. history score (0 to 30), laboratory score (0 to 20), growth score (0 to 20), physical examination score (0 to 20) and extraintestinal manifestation score (0 to 10).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"PCDAI Score","description":"Crohn's Disease Activity Index (PCDAI) was the sum (0 to 100) of the scores of 5 large categories. A larger PCDAI score represented higher disease activity. 5 large categories were as follows, i.e. history score (0 to 30), laboratory score (0 to 20), growth score (0 to 20), physical examination score (0 to 20) and extraintestinal manifestation score (0 to 10).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.43","spread":"4.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.71","spread":"9.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.75","spread":"6.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.43","spread":"5.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.86","spread":"8.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":"5.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.11","spread":"10.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"6.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.36","spread":"10.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.21","spread":"5.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.17","spread":"8.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":"6.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"8.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.92","spread":"4.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.08","spread":"9.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.18","spread":"12.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of PCDAI Score","description":"Crohn's Disease Activity Index (PCDAI) was the sum (0 to 100) of the scores of 5 large categories. A larger PCDAI score represented higher disease activity. 5 large categories were as follows, i.e. history score (0 to 30), laboratory score (0 to 20), growth score (0 to 20), physical examination score (0 to 20) and extraintestinal manifestation score (0 to 10).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.71","spread":"8.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.68","spread":"6.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.00","spread":"6.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.57","spread":"7.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.07","spread":"6.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.32","spread":"9.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.18","spread":"7.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.07","spread":"8.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.21","spread":"7.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.25","spread":"10.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.42","spread":"7.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.08","spread":"9.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.50","spread":"5.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.33","spread":"10.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.25","spread":"10.69"}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Who Achieved PCDAI-Based Remission Rate.","description":"Crohn's Disease Activity Index(PCDAI)-based remission was defined as a case where PCDAI on the evaluation day was decreased to not more than 10. Patients who satisfied the criterion for PCDAI response at least once in the evaluation at Week 2, 6 and 10 were defined as responders at Week 10.\n\nPCDAI was the sum (0 to 100) of the scores of 5 large categories. A larger PCDAI score represented higher disease activity. 5 large categories were as follows, i.e. history score (0 to 30), laboratory score (0 to 20), growth score (0 to 20), physical examination score (0 to 20) and extraintestinal manifestation score (0 to 10).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum TA-650 Concentration","description":"Median, Min and Max of serum TA-650 concentration at each evaluation point after dose of 5 mg/kg TA-650.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.62","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of the Patients Who Experienced an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":14},"commonTop":["Double stranded DNA antibody positive","Gastroenteritis","Nasopharyngitis","Headache","Influenza"]}}}